MiMedx
1234 Airport Road
Suite 105
Destin
Florida
32541
United States
Tel: 850-269-0000
Website: http://www.mimedx.com/
471 articles about MiMedx
-
MIMEDX to Host Second Quarter 2021 Operating and Financial Results Conference Call on August 4
7/20/2021
MiMedx Group, Inc., an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, announced that it will report operating and financial results for the second quarter ended June 30, 2021 after the market close on Tuesday, August 3, 2021.
-
MIMEDX to Present at the Raymond James 2021 Human Health Innovation Conference
6/16/2021
MiMedx Group, Inc.today announced that Timothy R. Wright, Chief Executive Officer, Peter M. Carlson, Chief Financial Officer, and Robert B. Stein, M.D., Ph.D., Executive Vice President, Research and Development, will present at the Raymond James 2021 Human Health Innovation Conference on Wednesday, June 23, 2021.
-
MIMEDX to Participate at the Jefferies Virtual Healthcare Conference - May 27, 2021
5/27/2021
MIMEDX Group, Inc. announced that Timothy R. Wright, Chief Executive Officer, Peter M. Carlson, Chief Financial Officer, and Robert B. Stein, M.D., Ph.D., Executive Vice President, Research and Development, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Friday, June 4, 2021 at 2:00 PM Eastern Time.
-
MIMEDX Reminds Shareholders to Pre-Register for the Upcoming Virtual 2021 Annual Meeting of Shareholders
5/25/2021
MIMEDX Group, Inc., an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, reminded shareholders to pre-register for the upcoming 2021 Annual Meeting of Shareholders, by no later than 10:00 a.m. Eastern on Wednesday, May 26, 2021.
-
MIMEDX Reminds Shareholders to Vote at the Upcoming Annual Meeting
5/12/2021
Vote FOR MIMEDX’s Experienced and Highly Qualified Directors and Governance Enhancement Proposals
-
MIMEDX Files Definitive Proxy Materials and Mails Letter to Shareholders Highlighting Actions Taken to Transform MIMEDX and Drive Significant Value for Shareholders
5/3/2021
MIMEDX Group, Inc., an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, announced that it has filed definitive proxy materials with the U.S. Securities and Exchange Commission in connection with its 2021 Annual Meeting of Shareholders, to be held virtually on May 27, 2021 at 10:00 a.m. Eastern Time at www.cesonlineservices.com/mdxg21_vm.
-
MiMedx Welcomes Dirk Stevens, Ph.D., as Senior Vice President, Quality Assurance and Regulatory Affairs
4/28/2021
Accomplished Regulatory Leader Joins MiMedx Management Team
-
MiMedx Announces First Quarter 2021 Financial and Operating Results
4/28/2021
MiMedx Group, Inc., an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, announced the filing of its first quarter 2021 Form 10-Q for the period ended March 31, 2021.
-
MiMedx to Host First Quarter 2021 Operating and Financial Results Conference Call on April 29
4/22/2021
MiMedx Group, Inc. (Nasdaq: MDXG) (“MiMedx” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today announced that it will report financial results for the first quarter ended March 31, 2021 after the market close on Wednesday, April 28, 2021.
-
Prescience Point Capital Management to Nominate Four Highly Qualified Director Candidates to MiMedx Board at 2021 Annual Meeting
4/16/2021
Prescience Point Capital Management, together with its affiliates ("Prescience Point"), a research-focused, catalyst-driven investment firm, announced today the nomination of four highly qualified director candidates to the Board of Directors (the "Board") of MiMedx Group, Inc.
-
MiMedx Confirms Receipt of Director Nominations from Prescience Point Capital Management
4/16/2021
MiMedx Group, Inc. (NASDAQ: MDXG) (“MiMedx” or the “Company”), an industry leader in utilizing birth tissue as a platform for regenerative medicine, today confirmed that Prescience Point Capital Management (“Prescience Point”) submitted a notice of nomination of Eiad Asbahi, Alfred G. Merriweather, Charlotte E. Sibley and William F. Spengler
-
MiMedx to Participate at Upcoming Investor Conferences
3/3/2021
MiMedx Group, Inc. (Nasdaq: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics company, today announced that management will be participating in the following virtual investor conferences: H.C. Wainwright Global Life Sciences Conference Presentation: Wednesday, March 10, 2021 available to view on-demand beginning at 2:00 PM ET
-
Reminder: MiMedx to Present at the 39th Annual J.P. Morgan Healthcare Conference
1/6/2021
MiMedx Group, Inc., an industry leader in advanced wound care and a therapeutic biologics company, announced that Timothy R. Wright, Chief Executive Officer, and Peter M. Carlson, Chief Financial Officer, will present at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13th at 4:30 PM EST.
-
MiMedx to Participate at the H.C. Wainwright BioConnect 2021 Conference
1/4/2021
MiMedx Group, Inc. (Nasdaq: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics company, today announced that Timothy R. Wright, Chief Executive Officer, and Dr. Robert Stein, Executive Vice President, Research & Development, will participate in a fireside chat at the H.C. Wainwright BioConnect 2021 Virtual Conference held January 11-14, 2021. The pre-recorded fireside chat will be avail
-
Parker H. “Pete” Petit, the former chief executive officer of wound care company MiMedx was convicted of fraud and making false statements to the U.S. Securities and Exchange Commission, following a months-long investigation into the company’s financial records. William Taylor, the company’s form...
-
MiMedx To Present At Canaccord Genuity Virtual MedTech & Diagnostics Forum
11/12/2020
MiMedx Group, Inc. (Nasdaq: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics company, today announced that Timothy R. Wright, MiMedx Chief Executive Officer, and Peter M. Carlson, MiMedx Chief Financial Officer, will present at the Canaccord Genuity Virtual MedTech & Diagnostics Forum on Thursday, November 19, 2020, beginning at 9:30 am, Eastern Time. A live webcast of the presentatio
-
MiMedx Shares to Commence Trading on Nasdaq on Wednesday, November 4, 2020
11/3/2020
MiMedx Group, Inc., an industry leader in advanced wound care and a therapeutic biologics company, confirmed that the Company’s common stock will commence trading on The Nasdaq Stock Market at the opening of trading on Wednesday, November 4, 2020, under the ticker symbol “MDXG”.
-
MiMedx Announces Preliminary Third Quarter 2020 Net Sales
9/21/2020
MiMedx Group, Inc., an industry leader in advanced wound care and a therapeutic biologics company, provided guidance regarding certain unaudited, preliminary third quarter financial results.
-
MiMedx Concludes Enrollment for Phase 3 Plantar Fasciitis Trial
9/17/2020
Research in Plantar Fasciitis Advances Understanding of Amniotic Tissue as Potential Treatment for Chronic Musculoskeletal Pain and Function Disorders MARIETTA, Ga., Sept. 17, 2020 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or “the Company”), an industry leader in advanced wound care and an emerging therapeutic biologics company, today announced the conclusion of enrollment for a Phase 3 study of plantar fasciitis, an inflammation of the fibrous tissue along the botto
-
MiMedx Launches EpiCord Expandable Placental Allograft as Addition to Market Leading Portfolio
9/14/2020
New Allograft Expands to Twice its Size and Provides a Protective Structure to Support the Wound Healing Cascade